文献速递姑息放疗与转移瘤放疗物理与技术

澳大利亚新南威尔士州骨转移姑息放疗单次分割使用模式与30天死亡率

Patterns of use of palliative radiotherapy fractionation for bone metastases and 30-day mortality.
PubMed 文献 · Radiother Oncol · 2020-11-18

该研究基于新南威尔士州中央癌症登记处2009至2014年数据,分析14,602疗程骨转移姑息放疗中单次分割放疗(SFRT)的使用模式及30天死亡率(30DM)。结果显示30%疗程为SFRT,高龄、低社会经济地位、偏远地区及合并症≥2的患者更可能接受SFRT;SFRT组30DM为21%,高于多分次放疗组的11%。结论认为SFRT在骨转移治疗中使用不足。

要点

  • 骨转移姑息放疗中仅30%疗程采用单次分割放疗(SFRT)。
  • SFRT更常用于高龄、低社会经济地位、偏远地区及合并症多的患者。
  • SFRT组30天死亡率为21%,高于多分次放疗组的11%。

核心结论

  • SFRT在新南威尔士州骨转移姑息治疗中使用不足,需开发工具推动其常规应用。

研究设计与样本

  • 基于人群的队列研究,纳入2009至2014年新南威尔士州中央癌症登记处记录的骨转移姑息放疗患者,共14,602疗程。

主要发现

  • 14,602疗程中30%为SFRT。
  • SFRT使用率:≥80岁34%对比<60岁28%,低社会经济地位35%对比高社会经济地位25%,偏远地区34%对比主要城市29%,合并症≥2者34%对比无合并症者29%。
  • SFRT组30天死亡率为21%,多分次放疗组为11%。

临床怎么用

  • 提示需关注骨转移姑息放疗中SFRT的应用不足,并识别影响分次选择的患者因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Adoption of single-fraction radiation therapy (SFRT) has not been universal in the palliative treatment of bone metastases, despite evidence supporting its safety and efficacy. The aim of this study was to assess SFRT use for bone metastases in New South Wales (NSW), Australia, and the rate of 30-day mortality (30DM). MATERIALS AND METHODS: This is a population-based cohort of patients who received palliative radiation therapy (RT) for bone metastases (2009-2014), as captured in the NSW Central Cancer Registry. A logistic regression model was used to identify factors associated with fractionation type. The proportion of patients dying within 30-days from treatment start date was calculated. RESULTS: Of the 14,602 courses of palliative RT delivered for bone metastases, 30% were SFRT. SFRT was more likely to be delivered to older patients: ≥80 years (34%) versus < 60 years (28%). Patients with lower socioeconomic status (SES) (35%) were more likely to receive SFRT compared with higher SES (25%). SFRT delivered to patients from outer regional area of residence (34%) were higher compared to those from the major city (29%). The proportion of SFRT delivered to patients with comorbidities ≥2 (34%) was higher than patients with no comorbidity (29%). SFRT was associated with higher 30DM of 21% compared with 11% for multi-fraction RT (MFRT). CONCLUSION: SFRT is underused for the treatment of bone metastases in NSW. This is an impetus to develop tools making SFRT obligatory in this setting unless there is good justification not to.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Batumalai V, Descallar J, Delaney GP, et al. Patterns of use of palliative radiotherapy fractionation for bone metastases and 30-day mortality. Radiother Oncol. 2020. PMID: 33217497. doi:10.1016/j.radonc.2020.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。